Organ and tissue transplant is now the treatment of choice for many end stage diseases. In
the recent years, there has been an increasing demand for organs but not a similar increase …

Although in previous studies most post-transplant lymphoproliferative disorders (PTLD) were
reported to derive from recipient cells, some cases derived from donor lymphocytes have …

Plasma cell diseases are a class of hematologic diseases that are sometimes present as
preexisting diagnoses prior to organ transplantation, causative factors leading to a need for …

Transplant recipients have elevated risk for plasma cell neoplasms (PCNs, comprising
multiple myeloma and plasmacytoma), but little is known about risk factors in the transplant …

Although post-transplant lymphoproliferative disorder (PTLD) is the second most common
type of cancer in kidney transplantation (KT), plasma cell neoplasia (PCN) occurs only rarely …

Post-transplant lymphoproliferative disorder (PTLD) is a rare but life-threatening
complication after solid organ and haematopoietic stem cell transplantation. A 40-year-old …

Chronic myeloid leukemia is a myeloproliferative disorder that may be treated with
hematopoietic stem cell transplantation (HSCT). While posttransplantation relapse of …

Posttransplant Lymphoproliferative Disorder (PTLD) is one of the most common
malignancies complicating solid organ transplantation. In contrast, PTLD accounts for a …

Prior research on donor monoclonal gammopathy of undetermined significance (MGUS) has
been inadequate regarding the risk for lymphoproliferative disease in solid organ …

Multiple myeloma (MM) developing after renal transplantation is rare. From January 1972 to
December 2011, a total of 1,485 patients underwent renal transplantation in Nagoya Daini …